Evidence map›Paper›PMID 40407096›Full record

ArticleGut microbes2025

Metaproteomics reveals age-specific alterations of gut microbiome in hamsters with SARS-CoV-2 infection.

Marybeth Creskey, Fabiola Silva Angulo, Qing Wu, Levi Tamming, Emily E F Fekete, Kai Cheng, Zhibin Ning, Angela Wang, Patrícia Brito Rodrigues, Vinícius de Rezende Rodovalho and 5 more

Abstract read
In one paragraph

Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marybeth CreskeyRegulatory Research Division, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, Canada.
Fabiola Silva AnguloUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Qing WuSchool of Pharmaceutical Sciences, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Levi TammingRegulatory Research Division, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, Canada.
Emily E F FeketeRegulatory Research Division, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, Canada.
Kai ChengSchool of Pharmaceutical Sciences, Faculty of Medicine, University of Ottawa, Ottawa, Canada.ORCID 0000-0002-6045-0244
Zhibin NingSchool of Pharmaceutical Sciences, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Angela WangRegulatory Research Division, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, Canada.
Patrícia Brito RodriguesUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Vinícius de Rezende RodovalhoLaboratory of Immunoinflammation, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.ORCID 0000-0003-4216-7143
Marco Aurélio Ramirez VinoloLaboratory of Immunoinflammation, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
Daniel FigeysSchool of Pharmaceutical Sciences, Faculty of Medicine, University of Ottawa, Ottawa, Canada.ORCID 0000-0002-5373-7546
Xuguang LiRegulatory Research Division, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, Canada.
Francois TrotteinUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.ORCID 0000-0003-3373-1814
Xu ZhangRegulatory Research Division, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, Canada.ORCID 0000-0003-2406-9478

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiome's pivotal role in health and disease is well established. SARS-CoV-2 infection often causes gastrointestinal symptoms and is associated with changes of the microbiome in both human and animal studies. While hamsters serve as important animal models for coronavirus research, there exists a notable void in the functional characterization of their microbiomes with metaproteomics. In this study, we present a workflow for analyzing the hamster gut microbiome, including a metagenomics-derived hamster gut microbial protein database and a data-independent acquisition metaproteomics method. Using this workflow, we identified 32,419 protein groups from the fecal microbiomes of young and old hamsters infected with SARS-CoV-2. We showed age-specific changes in the expressions of microbiome functions and host proteins associated with microbiomes, providing further functional insight into the interactions between the microbiome and host in SARS-CoV-2 infection. Altogether, this study established and demonstrated the capability of metaproteomics for the study of hamster microbiomes.

Indexed as

COVID-19Gastrointestinal MicrobiomeProteomicsAge FactorsAnimalsCricetinaeDisease Models, AnimalFecesMaleMesocricetusMetagenomicsSARS-CoV-2COVID-19data-independent acquisitiongut microbiomeMetaproteomics

Identifiers

PMID40407096
PMCPMC12118384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.